Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis

IMPORTANCE: Results of randomized clinical trials have demonstrated rituximab’s noninferiority to cyclophosphamide as induction therapy for antineutrophil cytoplasm antibody (ANCA)–associated vasculitides (AAV), with neither treatment having a specific advantage for granulomatosis with polyangiitis...

Descripción completa

Detalles Bibliográficos
Autores principales: Puéchal, Xavier, Iudici, Michele, Perrodeau, Elodie, Bonnotte, Bernard, Lifermann, François, Le Gallou, Thomas, Karras, Alexandre, Blanchard-Delaunay, Claire, Quéméneur, Thomas, Aouba, Achille, Aumaître, Olivier, Cottin, Vincent, Hamidou, Mohamed, Ruivard, Marc, Cohen, Pascal, Mouthon, Luc, Guillevin, Loïc, Ravaud, Philippe, Porcher, Raphaël, Terrier, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706346/
https://www.ncbi.nlm.nih.gov/pubmed/36441554
http://dx.doi.org/10.1001/jamanetworkopen.2022.43799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706346/
https://www.ncbi.nlm.nih.gov/pubmed/36441554
http://dx.doi.org/10.1001/jamanetworkopen.2022.43799

Ejemplares similares